MarcoRuellaMD

Hematologic Oncology

Assistant Professor of Medicine and Scientific Director, Lymphoma Program

Dr. Ruella is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Civic Center Blvd
Perelman Center for Advanced Medicine, SPE 8-112
Philadelphia, PA 19104
Phone+1 215-746-4880

Penn MedicinePost-Doctoral Fellowship, 2012 - 2018
University of TorinoSpecialty in Hematology, Clinical Hematology and Cell Therapy, cum Laude, 2008 - 2012
University of Torino Faculty of MedicineClass of 2007

PubMed

Journal Articles

Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell
Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
Nathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports

Abstracts/Posters

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

The Quest To Cure CLL: “Remarkable” Results With New StrategySeptember 2023
Interleukin-18 Secreting Autologous Anti-CD19 CAR T-cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-cell TherapyDecember 2022

Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune CellsDecember 29th, 2024
Keto Diet Metabolite May Power up CAR T Cells to Kill CancerDecember 9th, 2024
Keto Diet Might Increase Effectiveness of Certain Cancer TreatmentDecember 9th, 2024
Join now to see all